Shopping Cart
Remove All
Your shopping cart is currently empty
VNT-101
😃Good
Catalog No. T212391Cas No. 2894060-67-2
VNT-101 is an orally active inhibitor of influenza A virus (IAV). It disrupts NP-NP protein interactions, preventing NP oligomerization and destabilizing the viral ribonucleoprotein (RNP) complex, showing potent antiviral activity against multiple influenza A virus subtypes. In cell-based cytopathic effect (CPE) assays, VNT-101 has an EC50 value of 4-5 nM, while it measures 4-8 nM in neuraminidase (NA) assays and 21-45 nM in ribonucleoprotein (RNP) assays. Demonstrating strong in vivo antiviral efficacy, VNT-101 protects against lethal H1N1 virus infection in mice. VNT-101 is applicable to influenza A virus infection research.
VNT-101
😃Good
Catalog No. T212391Cas No. 2894060-67-2
VNT-101 is an orally active inhibitor of influenza A virus (IAV). It disrupts NP-NP protein interactions, preventing NP oligomerization and destabilizing the viral ribonucleoprotein (RNP) complex, showing potent antiviral activity against multiple influenza A virus subtypes. In cell-based cytopathic effect (CPE) assays, VNT-101 has an EC50 value of 4-5 nM, while it measures 4-8 nM in neuraminidase (NA) assays and 21-45 nM in ribonucleoprotein (RNP) assays. Demonstrating strong in vivo antiviral efficacy, VNT-101 protects against lethal H1N1 virus infection in mice. VNT-101 is applicable to influenza A virus infection research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | VNT-101 is an orally active inhibitor of influenza A virus (IAV). It disrupts NP-NP protein interactions, preventing NP oligomerization and destabilizing the viral ribonucleoprotein (RNP) complex, showing potent antiviral activity against multiple influenza A virus subtypes. In cell-based cytopathic effect (CPE) assays, VNT-101 has an EC50 value of 4-5 nM, while it measures 4-8 nM in neuraminidase (NA) assays and 21-45 nM in ribonucleoprotein (RNP) assays. Demonstrating strong in vivo antiviral efficacy, VNT-101 protects against lethal H1N1 virus infection in mice. VNT-101 is applicable to influenza A virus infection research. |
| In vitro | VNT-101 demonstrates potent anti-influenza A virus activity in RNP assays, with an EC50 of 45 nM against the H1N1/California subtype and 21 nM against the H3N2/Alaska subtype. In NA assays, VNT-101 exhibits strong inhibition of viral neuraminidase, with an EC50 of 8 nM for H1N1/PR8 and 4 nM for H3N2/Alaska. Additionally, in CPE assays, VNT-101 effectively inhibits virus-induced cytopathic effects, achieving an EC50 of 5 nM against H1N1/PR8 and 4 nM against H3N2/Alaska. |
| In vivo | VNT-101 (1-30 mg/kg, administered orally twice daily for 5 days) exhibits anti-influenza activity in Balb/c mice infected with the H1N1 virus. |
| Molecular Weight | 456.41 |
| Formula | C21H23F3N2O6 |
| Cas No. | 2894060-67-2 |
| Smiles | C(F)(F)(F)C1=C(C=C(C(N)=O)C(=O)N1)C2=CC=C(OC[C@H]3O[C@](COC)(C)COC3)C=C2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy VNT-101 | purchase VNT-101 | VNT-101 cost | order VNT-101 | VNT-101 chemical structure | VNT-101 in vivo | VNT-101 in vitro | VNT-101 formula | VNT-101 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.